‘Pharma Bro’ Shkreli Calls SLS Results ‘Sketch,’ Compares Leukemia Vaccine Data To Capricor’s Deramiocel

SELLAS Life Sciences (SLS) reported that its REGAL trial of the galinpepimut-S cancer vaccine met the primary overall survival endpoint, with median survival of 24 months vs. 14.7 months for the best available treatment. Shares jumped over 200% on the news. Former pharmaceutical executive Martin Shkreli criticized the data, comparing it to Capricor Therapeutics' (CAPR) Deramiocel data and predicting FDA rejection.

Original reporting
Published Nov 17, 2026, 8:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
‘Pharma Bro’ Shkreli Calls SLS Results ‘Sketch,’ Compares Leukemia Vaccine Data To Capricor’s Deramiocel — source image
Decision brief

The 30-second read

$SLSNeutralMed
01

Why it matters

For SLS, the actionable driver is the newly reported primary OS endpoint plus immediate narrative pushback that can affect near-term positioning until secondary analyses are presented. For CAPR, the actionable driver is the specific upcoming FDA decision date and a bearish public opinion that can influence sentiment and options pricing.

02

Market read

This is a biotech catalyst-and-narrative story: a fresh OS endpoint for SLS triggers a surge, while Shkreli’s critique raises fragility concerns; CAPR faces a near-term FDA decision with added bearish commentary.

03

What to watch

The article does not detail hazard ratios, confidence intervals, or the fragility index definition; traders may be reacting to narrative rather than full statistical context, and SLS’s FDA application timing is not until first half of 2027.

Relevance 7/10Novelty 6/10Timing: today’s reaction to REGAL OS endpoint, with FDA decision risk for Deramiocel into Nov. 22

Background

The piece centers on Shkreli’s skepticism after SELLAS reported primary overall survival success in its REGAL trial, and it draws a comparison to Capricor’s Deramiocel ahead of an FDA decision by Nov. 22.

Company-level read

Ticker impact

$SLSNeutralMedium confidence
Context

SELLAS reported late-stage REGAL trial met the primary overall survival endpoint, with median survival 24 months vs 14.7 months, driving a sharp jump in shares.

Expected impact

Likely two-way trading as investors weigh the positive OS endpoint against concerns about fragility and pending secondary analyses and FDA timing.

Evidence & confidence

The article contains a fresh clinical-trial primary endpoint disclosure plus a same-day high-profile critique that could swing sentiment before conference/publication and the 2027 FDA filing window.

$CAPRBearishMedium confidence
Context

Capricor’s Deramiocel FDA decision is expected by Nov. 22, and Shkreli argues the agency will not approve it, linking the debate to Deramiocel data.

Expected impact

Likely downside pressure or elevated implied volatility if traders treat the commentary as a bearish signal ahead of the FDA decision.

Evidence & confidence

While the article does not add new Deramiocel trial facts, it highlights a specific upcoming regulatory date and a direct bearish claim that can move positioning.

Market effects

Reinforces high sensitivity of oncology vaccine and cell-therapy names to overall survival endpoint interpretation and fragility narratives.

Primarily US biotech sentiment; no direct macro release or cross-asset catalyst described.

Limited, mostly affects US-listed biotech risk appetite around FDA decision timelines.

Counterpoint

Shkreli’s “fragile” framing may overstate the risk; the company is still pursuing secondary endpoint analyses and planned conference and publication, which can clarify robustness.

Key entities

  • SELLAS Life Sciences

    Reported REGAL trial met the primary overall survival endpoint in relapsed AML second remission, with median survival 24 months vs 14.7 months.

  • Capricor Therapeutics

    Deramiocel FDA decision expected by Nov. 22; Shkreli opined the drug will not be approved.

  • Martin Shkreli

    Publicly criticized SLS results as statistically fragile and compared them to Deramiocel data.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$NVDAMed

NVDA Earnings Spark Tech Rally As US Futures Climb — BABA, INTC, ASTS In Focus

Nvidia (NVDA) reported strong Q3 earnings, beating revenue and EPS estimates, driving early premarket gains. Alibaba (BABA) faces scrutiny over ties to a suspected Chinese spy. Intel (INTC) reportedly laid off employees as part of restructuring. Capricor Therapeutics (CAPR) awaits FDA decision on its DMD therapy. AST SpaceMobile (ASTS) faces investor concerns over rocket development. Klarna (KLAR) reported better-than-expected Q3 revenue but missed adjusted EPS estimates.

$NVDAMed

Futures Climb As Nvidia Earnings Boost AI Trade — BABA, INTC, ASTS, CAPR In Focus

Nvidia reported 103% revenue growth to $115.8B, beating estimates. U.S. stock futures rose early Wednesday. Alibaba faces scrutiny over ties to a suspected Chinese spy. Intel confirmed layoffs. Capricor awaits FDA decision on Deramiocel. AST SpaceMobile faces investor concerns over rocket development. Klarna reported Q3 revenue of $1.009B, narrowing losses. Target, Palo Alto Networks, Lowe's, and TJX are set to report earnings.

$SLSHighAI 9/10

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here

Sellas Life Sciences (SLS) reported positive Phase 3 trial results for its cancer vaccine, Galinpepimut-S (GPS), showing a 24-month median survival vs. 14.7 months in the control group. The company plans to meet with the FDA and aims to file for approval in early 2027. SLS also announced a $150M share offering to fund further development. Analysts and investors reacted positively, with some noting potential for expedited approval and broader applications.